It was announced a few days ago that the Ministry of Health will start supplying the Unified Health System (SUS) with medicines that will help in the treatment of people with Parkinson’s syndrome, enabling the body to treat more diseases that may affect the population. The medication provided will be rivastigmine.
The announcement of new treatments in the SUS was made last Thursday (28/11) during the 11th Ordinary Meeting of the Tripartite Intermanagers Commission (CIT). This medicine, which will be provided by the Ministry, helps the patient to have a better quality of life, as it helps with cognitive function.
According to data provided by the government itself, this initiative is expected to benefit more than 33 thousand people across Brazil, providing a better quality of life and reinforcing treatment for those in need.
Click here to read more
1733232451
#SUS #free #treatment #patients #Parkinsons #dementia
How can continued investment in research and accessibility help address these challenges?
**News Anchor:** Welcome back to the show. Joining us today is Dr. Silva, a neurologist with expertise in Parkinson’s disease. Dr. Silva, thank you for being here.
**Dr. Silva:** It’s a pleasure to be here.
**News Anchor:** The Ministry of Health recently announced that rivastigmine will be made available through the SUS to help treat Parkinson’s. What are your thoughts on this development and its potential impact?
**Dr. Silva:** This is indeed positive news for those living with Parkinson’s in Brazil. Rivastigmine can significantly improve cognitive function in patients, leading to a better quality of life. Making it accessible through the SUS ensures that more people, regardless of their financial means, can benefit from this treatment.
**News Anchor:** How many people might this directly impact?
**Dr. Silva:** The government estimates that over 33,000 people across Brazil could benefit from this initiative. This is a substantial number, and it speaks to the widespread need for effective treatments for Parkinson’s in our country.
**News Anchor:**
This is a major step towards a more comprehensive approach to Parkinson’s care.
What do you think are some of the biggest challenges in treating Parkinson’s, and how can continued investment in research and accessibility play a role?
